Hikal P/E Ratio
Hikal (HIKAL) P/E ratio is not applicable — EPS (TTM) ₹-3.96. See Healthcare peers with valid P/E ratios below.
P/E Ratio Status
N/A
Loss Making
Company is currently reporting losses
P/E Ratio Not Applicable
Company reported a loss in the most recent quarter. P/E ratio is not meaningful for loss-making periods.
Current EPS: ₹-3.96
Recent Quarterly Performance
| Quarter | EPS (₹) | Net Profit (₹ Cr) | Status |
|---|---|---|---|
| Mar 2026 | 1.17 | 14 | Profit |
| Sept 2025 | -2.83 | -35 | Loss |
| Mar 2025 | 4.07 | 50 | Profit |
| Jun 2025 | -1.82 | -22 | Loss |
| Dec 2025 | -0.48 | -6 | Loss |
| Sept 2024 | 1.48 | 18 | Profit |
| Mar 2024 | 2.76 | 34 | Profit |
| Jun 2024 | 0.41 | 5 | Profit |
Healthcare Peers with Valid P/E Ratios — HIKAL Comparison
Healthcare sector average P/E 55.64, median 31.4 — HIKAL excluded (negative EPS).
Sector Average PE
55.64
Sector Median PE
31.4
Lowest PE
2.86
Profitable Companies
195
| Company | Symbol | P/E Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Murae Organisor | MURAE | 2.86 | ₹41 | Low |
| Phaarmasia | PHRMASI | 3.61 | ₹64 | Low |
| Sunrest Lifescience | SUNREST | 3.76 | ₹30 | Low |
| Sun Pharma Advanced Rese… | SPARC | 4.76 | ₹7,399 | Low |
| Shelter Pharma | SHELTER | 5.23 | ₹47 | Low |
| Dipna Pharmachem | DPL | 5.39 | ₹14 | Low |
| JFL Life Sciences | JFLLIFE | 5.41 | ₹68 | Low |
| Amwill Health Care | AMWILL | 7.26 | ₹83 | Low |
| Zenith Drugs | ZENITHDRUG | 7.69 | ₹84 | Low |
| Galaxy Medicare | GML | 7.8 | ₹27 | Low |
Related Analysis
- For live price, revenue and the complete fundamental profile, see Hikal share price screener.
- Read Hikal dividend policy for the complete payout history and dividend yield track record.
- See HIKAL price book multiple to compare market price against book value per share.